NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women

Not Yet RecruitingN/A

Sponsor: MedicalExcellence

Conditions: Breast Cancer

Countries: South Korea

This study evaluates the long-term effects of adding 2 years of ovarian function suppression (OFS) to tamoxifen therapy in young premenopausal women with hormone receptor-positive breast cancer after chemotherapy. The study will assess recurrence, breast cancer-specific survival, and overall survival beyond 10 years to determine the long-term benefits of OFS treatment.

Eligibility overview

Sex: FEMALE

Age: 20 Years to 45 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Premenopausal women with hormone receptor-positive breast cancer enrolled in the ASTRRA trial (NCT00912548).

Patients enrolled and randomized in the ASTRRA study between March 1, 2009, and July 17, 2018 (excluding screening failures).

Patients with available long-term follow-up information.

Exclusion Criteria:

* Patients with primary breast cancer meeting any of the following criteria:

Hormone receptor-negative breast cancer Unknown hormone receptor status

Patients with a history of hysterectomy or bilateral oophorectomy

Patients with breast sarcoma or squamous cell carcinoma of the breast

Patients with a history of malignancy other than breast cancer within 5 years prior to enrollment

Patients with thrombocytopenia

Patients who had previously received CMF chemotherapy (cyclophosphamide, methotrexate, and fluorouracil)

Locations (1)

Seoul, Sondpagu, South Korea